Last updated: 11/03/2018 19:08:54
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects with Impaired Renal Function and Healthy Subjects with Normal Renal Function (AT1001-015)
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects with Impaired Renal Function and Healthy Subjects with Normal Renal Function (AT1001-015)
Trial description: This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects with mild, moderate, and severe renal impairment.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
N\A
Primary outcomes:
Number of subjects with adverse events to assess safety and tolerability
Timeframe: Day 1 to Day 10 (+1)
Clinical laboratory test values to assess safety and tolerability
Timeframe: Day -28 to Day 10 (+1)
Vital signs to assess safety and tolerability
Timeframe: Day -28 to Day 10 (+1)
Physician examination to assess safety and tolerability
Timeframe: Day -28 to Day 10 (+1)
Measure of ECG to assess safety and tolerability
Timeframe: Day -28 to Day 10 (+1)
Secondary outcomes:
Maximum observed concentration (Cmax) of AT1001
Timeframe: Day 1 to Day 6
Time to achieve maximum concentration (Tmax) of AT1001
Timeframe: Day 1 to Day 6
Apparent terminal elimination half life (t1/2 ) of AT1001
Timeframe: Day 1 to Day 6
Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001
Timeframe: Day 1 to Day 6
Area under the concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001
Timeframe: Day 1 to Day 6
Apparent terminal elimination rate constant for AT1001
Timeframe: Day 1 to Day 6
Oral clearance of AT1001
Timeframe: Day 1 to Day 6
Oral volume of distribution of AT1001
Timeframe: Day 1 to Day 6
Interventions:
Drug: AT1001 150 mg
Enrollment:
32
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Fabry disease
Product
migalastat
Collaborators
Amicus Therapeutics
Study date(s)
August 2011 to April 2012
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 75 Year
Accepts healthy volunteers
yes
- Inclusion Criteria
- All subjects
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion Criteria All subjects -males or females aged 18 to 70 years inclusive (subjects with normal renal function, mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with severe renal impairment) -body mass index 18.0 to 40.0 kilogram (kg)/square meter (m^2) inclusive -females who are non-pregnant, non-lactating, or postmenopausal for >=1 year, surgically sterile for >= 90 days, or agree to use approved methods of contraception -males will be sterile or use approved methods of contraception -understands and signs informed consent form Healthy subjects with normal renal function -negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in -good health with no clinically significant medical history, physical examination, vital signs, or 12-lead ECG -clinical laboratory tests within the reference range or not clinically significant -normal renal function (estimated CLcr >90 mL/min) at Screening Subjects with mild, moderate or severe renal impairment -negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in or verification of a prescription for a positive test -renal impairment (estimated CLcr <90 mL/min) -evidence of stable renal impairment defined as two separate estimated CLcr values within 25% -clinical laboratory results consistent with their renal condition or of no clinical significance for the study -abnormal laboratory values must not be clinically significant. Anemia secondary to renal disease is acceptable if hemoglobin is ≥9 g/dL and no clinically significant symptoms. Liver enzymes and bilirubin must be below twice the upper normal level -subjects with renal impairment must have stable underlying medical conditions < 90 days before study start -stable medication regimen(s) (no new drug(s) or changed dosage(s) <30 days before study drug) -in good general health, allowing for concurrent illnesses associated with chronic kidney disease Exclusion Criteria: All subjects: -history of hypersensitivity or allergies to any drug, unless approved by the Investigator and reviewed by Sponsor/Medical Monitor -participation in a study with receipt of an investigational drug < 5 half-lives or 30 days (whichever is longer) before Check-in -use of alcohol, grapefruit, or caffeine-containing foods or beverages < 72 hours before Check-in, unless approved by the Investigator and reviewed by the Sponsor/Medical Monitor -poor peripheral venous access -whole blood donation < 56 days before dosing or plasma donation < 14 days before dosing -receipt of blood products < 2 months before Check-in -history or presence of any clinically significant abnormal ECG -history of alcoholism or drug addiction < 1 year before Check-in -positive test for HIV antibody, HBsAg or anti-HCV -pregnant or breastfeeding Healthy subjects with normal renal function: -use of any tobacco- or nicotine-containing products < 6 months before Check-in -clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease putting the subject at increased risk or could interfere with study objectives -screening laboratory values outside normal range and deemed clinically significant by the Investigator -use of a prescription drug < 14 days of dosing or a non-prescription drug < 7 days before dosing or need of concomitant medication during the study Subjects with mild, moderate, or severe renal impairment: -unstable disease (concurrent medical conditions that have changed significantly < 90 days) -changes in concomitant prescription medications < 30 days before dosing or expected changes during study -use of new non-prescription medication < 30 days before dosing
- renal transplant -acute or chronic non-renal condition limiting the subject’s ability to complete and/or participate in the study
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2012-23-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website